Results 211 to 220 of about 3,116,614 (307)

Supplementary Figure 3 from SPARC Stabilizes ApoE to Induce Cholesterol-Dependent Invasion and Sorafenib Resistance in Hepatocellular Carcinoma [PDF]

Shan Wan, Quan-Yao He, Yun Yang, Feng Liu, Xue Zhang, Xin Guo, Hui Niu, Yi Wang, Yi-Xuan Liu, Wen-Long Ye, Xiuming Li, Xue-Mei ZhuanSun, Pu Sun, Xiao‐Shun He, Guang Hu, Kai Breuhahn, Hua Zhao, Guo-Qiang Wu, Hua Wu   +18 more
openalex   +1 more source

MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe

Cancer Science, Volume 117, Issue 2, Page 377-392, February 2026.
MASTL drives hepatocellular carcinoma (HCC) progression and paclitaxel resistance by triggering mitotic catastrophe. Depletion of MASTL induces DNA damage and promotes mitotic catastrophe, leading to cell death in HCC. MASTL‐mediated mitotic catastrophe depends on PP2A‐B55α activity, suggesting a novel therapeutic target for overcoming chemotherapy ...
Ke Wang, Ziwei Fu, Chuan Xiong, Jing Zhang, Qiang Luo   +4 more
wiley   +1 more source

Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma

Biology Direct
Background Hepatocellular carcinoma (HCC) is one of the most common as well as leading causes of mortality worldwide, and sorafenib is the first-line treatment in HCC patients. Unfortunately, drug resistance to sorafenib often develops.
Xiangbo Huang, Nan Yi, Pengfei Zhu, Jian Gao, Jun Lv   +4 more
doaj   +1 more source

T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Hepatocellular carcinoma (HCC), accounting for over 90% of primary liver cancers, remains a major global challenge for healthcare professionals. While immunotherapy has transformed the landscape of cancer treatment, its success is often limited by immune resistance, particularly through T cell exhaustion which remains a major barrier to ...
Kosar Nouri, Negar Asadollahei, Yasamin Haghir‐Sharif‐Zamini, Homeyra Seydi, Mahsa Salehi, Mehrnaz Mesdaghi, Mustapha Najimi, Massoud Vosough   +7 more
wiley   +1 more source

Underlying mechanism of sorafenib resistance in hepatocellular carcinoma: a bioinformatics study based on validated resistance-related genes [PDF]

, 2021
Song Yu, Peng Gao, Haiying Ding, Gaoqi Xu, Yan Hu, Yinghui Tong, Wenxiu Xin, Liwen Zhang, Miaolian Wu, Fang Luo   +9 more
openalex   +1 more source

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background/Aims Immune checkpoint inhibitors (ICIs) have transformed advanced HCC treatment. The benefit of sequential immunotherapy after prior ICI failure remains unclear. Given the expanded use of atezolizumab plus bevacizumab (Ate/Bev) over the past 5 years, we explored the real‐world outcomes of nivolumab plus ipilimumab (Nivo/Ipi) in ...
Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon   +15 more
wiley   +1 more source

Long noncoding RNA DDX11-AS1 represses sorafenib-induced ferroptosis in hepatocellular carcinoma cells via Nrf2-Keap1 pathway

Discover Oncology
Sorafenib, a first-line therapeutic option for advanced hepatocellular carcinoma (HCC), faces a formidable challenge in the form of emerging resistance.
Liang Wang, Liming Wang
doaj   +1 more source

Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma

, 2019
Peter Dietrich, Anne Gaza, Laura Wormser, Valerie Fritz, Claus Hellerbrand, Anja‐Katrin Bosserhoff   +5 more
openalex   +1 more source

COPS5 Triggers Ferroptosis Defense by Stabilizing MK2 in Hepatocellular Carcinoma

Advanced Science
Sorafenib, which is proven to serve as a potent ferroptosis inducer, is used as a first‐line treatment for patients with advanced hepatocellular carcinoma (HCC), but it has limited clinical benefits, mainly due to drug resistance.
Ai‐Ling Luo, Wen‐Ying Zheng, Qiong Zhang, Yan Yuan, Mei‐Qi Li, Kai Du, An‐Ran Gao, Li‐Jun Pei, Jie Xie, Wen‐Hao Chen, Long Zhang, Xiu‐Zhu Guo, Xiao‐Ran Yang, Chao Zeng, Guo‐Hua Yang, Min Deng   +15 more
doaj   +1 more source

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma [PDF]

, 2021
Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Kensei Nishida, Tetsu Tomonari, Misato Hirata, Masahiro Bando, Yoshifumi Kida, Takahiro Tanaka, Tomoyuki Kawaguchi, Hironori Wada, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshihito Tanahashi, Tetsuji Takayama   +16 more
openalex   +1 more source